Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Working Capital Changes (2016 - 2025)

ImmunityBio (IBRX) has disclosed Other Working Capital Changes for 12 consecutive years, with $82000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes rose 321.62% to $82000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $324000.0, a 197.25% increase, with the full-year FY2025 number at $570000.0, up 422.94% from a year prior.
  • Other Working Capital Changes was $82000.0 for Q4 2025 at ImmunityBio, down from $4.0 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $18.9 million in Q4 2022 to a low of -$3.9 million in Q2 2021.
  • A 5-year average of $1.1 million and a median of $82000.0 in 2025 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: plummeted 36950.0% in 2021, then skyrocketed 11328.57% in 2025.
  • ImmunityBio's Other Working Capital Changes stood at $4.4 million in 2021, then soared by 329.88% to $18.9 million in 2022, then crashed by 98.93% to $201000.0 in 2023, then plummeted by 118.41% to -$37000.0 in 2024, then skyrocketed by 321.62% to $82000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Other Working Capital Changes are $82000.0 (Q4 2025), $4.0 million (Q2 2025), and $242000.0 (Q1 2025).